

Outcome of the Process - Public Consultation on proposed fees for Human Medicines, Compliance, Medical Devices and Veterinary Medicines for 2024

1 RESPONSE TO THE CONSULTATION

The HPRA received one response on the Human Medicines, Compliance and Medical Devices fee consultation and no responses on the Veterinary Medicines consultation.

The HPRA welcomes all the suggestions and contributions made as part of our fee consultation. This document is a summary of the outcome of the consultation.

2 SUMMARY OF RESPONSES RECEIVED

One response was received from a human medicines marketing authorisation holder. The response agreed with the proposals including the general minor increase of 1.5%.

3 CONCLUSION

Although not identified as part of the consultation process, in the light of the end of the Brexit exemptions and the introduction of the Windsor Framework, the HPRA have decided not to add any increase to the annual fee for dormant authorisations to help maintain those authorisations.

The HPRA's primary objective is the protection of public health but in delivering this we are committed to providing a first class service to the industry we regulate. We will continue to review the cost base of the HPRA and related fees. As always, we commit to reviewing our fees annually to ensure that the fee levels are appropriate to the functions and costs of the HPRA.

Consequently, as we are required to cover our costs with fee income, we propose to submit the fee structure as outlined in the original consultation document to the Minister for Health and the Minister for Agriculture, Food and the Marine for approval.

We would like to thank all those that contributed to the consultation process.

HPRA
Finance, Corporate and International Department
09 November 2023